CEO
Stephen Isaacs
Employees
231
Industry
Pharmaceutical Preparation Manufacturing
chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
Loading...
Open
40.31
Mkt cap
2.7B
Volume
3.3M
High
40.51
P/E Ratio
-12.47
52-wk high
40.51
Low
40.30
Div yield
N/A
52-wk low
18.34
Portfolio Pulse from richadhand@benzinga.com
August 08, 2023 | 12:41 pm
Portfolio Pulse from Benzinga Insights
August 01, 2023 | 12:20 pm
Portfolio Pulse from richadhand@benzinga.com
August 01, 2023 | 10:29 am
Portfolio Pulse from Benzinga Newsdesk
July 28, 2023 | 12:03 pm
Portfolio Pulse from richadhand@benzinga.com
June 21, 2023 | 12:28 pm
Portfolio Pulse from richadhand@benzinga.com
June 14, 2023 | 1:19 pm
Portfolio Pulse from richadhand@benzinga.com
June 13, 2023 | 11:25 am
Portfolio Pulse from richadhand@benzinga.com
June 13, 2023 | 10:16 am
Portfolio Pulse from richadhand@benzinga.com
June 13, 2023 | 10:12 am
Portfolio Pulse from Benzinga Newsdesk
June 12, 2023 | 8:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.